chop shop ?
all the secondary endpoints showed improvement it was only the primary endpoint that missed
Pfizer on the other hand the secondary endpoints showed nothing
I mean the writing was on the wall from the start unless you listened to itsgas - the “failure” was backed with all positives outside of the primary hence the flash crash ….
I mean if you couldn’t see the obvious at the start the fact Roche initiated Elevidy’s marketing authorisation applications in Europe first half of this year only highlighted their opinion on those secondary endpoints pulling it through.
FDA approves Sareptas Srp901 for the whole population, page-22
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |